[Effectiveness of proxyphylline in chronic obstructive pulmonary disease (author's transl)].
The bronchospasmolytic action of proxyphylline given intravenously in a dosage of 16 mg/kg body weight was assessed by spirometry and bodyplethysmography in 12 patients with chronic obstructive pulmonary disease. Proxyphylline serum levels were estimated in parallel repeatedly. In the majority of patients a bronchospasmolytic effect could be established (lowering of airway resistance by 30% in 9 and by 40% in 7 patients). In some an action was demonstrated for up to 4 hours. There were no serious side effects and in particular no adverse cardiovascular reactions or skeletal muscular tremor.
D000328:Adult; D000368:Aged; D000628:Aminophylline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D002000:Bronchospirometry; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010993:Plethysmography, Whole Body; D013806:Theophylline / Q000031:analogs & derivatives; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced
C003237:proxyphylline; D000628:Aminophylline; D013806:Theophylline
Proxyphyllinwirkung bei chronisch-obstruktiven Atemwegserkrankungen.